Endocrinology

Episodes 1-4 of 4

• • 

    

    Pam R. Taub, MD, FACC, FASPC

    Peer

  • 

    

    George L. Bakris, MD

    Peer

  • 

    

    Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)

    Peer

  4

  

  RestartResume

  Reducing Morbidity and Mortality in Patients with CKD in T2D: New Late-Breaking Data

  RestartResume

  Reducing Morbidity and Mortality in Patients with CKD in T2D: New Late-Breaking Data

  0.50 credits

  Reducing Morbidity and Mortality in Patients with CKD in T2D: New Late-Breaking…

  0.50 credits

• • 

    

    Charles P. Vega, MD

    Peer

  • 

    

    Rajeev Raghavan, MD, M.Ed, FASN

    Peer

  1

  

  RestartResume

  Anemia in Chronic Kidney Disease: Improved Patient Outcomes Needed STAT!

  RestartResume

  Anemia in Chronic Kidney Disease: Improved Patient Outcomes Needed STAT!

  0.50 credits

  Anemia in Chronic Kidney Disease: Improved Patient Outcomes Needed STAT!

  0.50 credits

• • 

    

    Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA

    Peer

  • 

    

    Charles P. Vega, MD

    Peer

  9

  CME/CE Broadcast Replay

  

  RestartResume

  Let’s Examine Collaborative Patient Management in ASCVD Risk Reduction

  RestartResume

  Let’s Examine Collaborative Patient Management in ASCVD Risk Reduction

  1.00 credit

  Let’s Examine Collaborative Patient Management in ASCVD Risk Reduction

  1.00 credit

• • 

    

    Peter Rossing, DMSc, MD

    Peer

  • 

    

    Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)

    Peer

  • 

    

    Matthew R. Weir, MD

    Peer

  13

  

  RestartResume

  New Insights into the Management of CKD in T2D: The Role of MRA Therapies

  RestartResume

  New Insights into the Management of CKD in T2D: The Role of MRA Therapies

  0.25 credits

  New Insights into the Management of CKD in T2D: The Role of MRA Therapies

  0.25 credits